Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma.
Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma.
复制标题
DOI：
10.1016/j.gastha.2022.07.020
复制
发表时间：
2023-01-01
期刊：
影响因子：
--
通讯作者：
Saruta, Masayuki
中科院分区：
文献类型：
--
作者：
Oikawa, Tsunekazu;Yamada, Kohji;Saruta, Masayuki
背景和目的：肝细胞癌（HCC）是最常见的恶性肿瘤，预后差。迫切需要鉴定一种可检测早期和常规肿瘤标志物阴性HCC的替代生物标志物。我们发现蛋白激酶C δ（PKC δ）特异性地从HCC细胞系分泌到细胞外空间，并有助于肿瘤的发展，并且其血清水平在HCC患者中升高。本研究旨在评估血清PKC δ检测HCC在慢性肝病（CLD）patients.Methods的实用价值：血清PKC δ水平在313例CLD患者和无HCC（n= 187和126，分别）采用夹心酶联免疫吸附试验测定。结果：HCC患者血清PKC δ水平明显高于CLD患者，且与AFP、DCP的相关性无统计学意义（P> 0.05）。PKC δ在区分HCC和CLD患者中具有较高的敏感性和特异性。亚组分析显示，PKC δ对HCC的诊断性能与AFP和DCP相当，大约40%的AFP/DCP双阴性HCC患者PKC δ阳性。PKC δ在检测孤立性小肝癌（即极早期）方面的诊断性能优于AFP和DCP。结论：血清PKC δ是一种新的肝癌生物标志物，与常规标志物既相互独立又相互补充。具体而言，PKC δ可能有助于检测非常早期或AFP/DCP双阴性HCC。
Backgrounds and Aims: Hepatocellular carcinoma (HCC) is the most common cancer with a poor prognosis. Identification of an alternative biomarker that can detect early-stage and conventional tumor marker-negative HCC is urgently needed. We found that protein kinase C delta (PKCdelta) is specifically secreted from HCC cell lines into extracellular space and contributes to tumor development and that its serum levels were elevated in HCC patients. This study aimed to assess the practical usefulness of serum PKCdelta for detecting HCC in chronic liver disease (CLD) patients.Methods: Serum PKCdelta levels in 313 CLD patients with and without HCC (n= 187 and 126, respectively) were measured using a sandwich enzyme-linked immunosorbent assay. The diagnostic performance of PKCdelta for HCC was evaluated using the receiver operating characteristic curve analysis and was compared with that of conventional markers, alpha-fetoprotein (AFP), and des-gamma-carboxy prothrombin (DCP).Results: Serum PKCdelta levels in HCC patients were significantly higher than those in CLD patients without HCC. PKCdelta distinguished HCC patients from CLD patients without HCC, with high sensitivity and specificity. Subgroup analyses revealed that the diagnostic performance of PKCdelta for HCC was comparable to that of AFP and DCP, and that approximately 40% of AFP/DCP double-negative HCC patients were positive for PKCdelta. PKCdelta yielded better diagnostic performance for detecting solitary small-sized (ie, very early stage) HCC than AFP and DCP. There was no significant correlation between serum PKCdelta and AFP/DCP levels.Conclusion: Serum PKCdelta is a novel HCC biomarker, which is independent of and complementary to conventional markers. Specifically, PKCdelta may be useful for detecting very early-stage or AFP/DCP double-negative HCC.